modelR06AX24
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Epinastine | |
| ATC code: | R06AX24 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 87 | L |
| clearance: | 42 | L/h |
| other parameters in model implementation | ||
Epinastine is a second-generation antihistamine (H1 receptor antagonist) used primarily for the treatment of allergic conjunctivitis and, in some countries, allergic rhinitis. It is approved for topical ophthalmic use and is available in some markets, but not all.
Pharmacokinetics
Pharmacokinetic parameters estimated for healthy adult individuals; no peer-reviewed human pharmacokinetic publication was identified at time of report.
References
Sarashina, A, et al., & Igarashi, T (2005). Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. British journal of clinical pharmacology 59(1) 43–53. DOI:10.1111/j.1365-2125.2005.2250 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15606439
Jang, JH, & Jeong, SH (2025). Population modeling of pharmacokinetic variability of epinastine, a histamine H. Naunyn-Schmiedeberg's archives of pharmacology None –. DOI:10.1007/s00210-025-04299-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40439884
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)